Carlos Alfaro Alegría-rekin lankidetzan egindako argitalpenak (7)

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

2011

  1. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  2. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

2005

  1. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8

    International Journal of Cancer, Vol. 116, Núm. 2, pp. 275-281

  2. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas

    Journal of Clinical Oncology, Vol. 23, Núm. 5, pp. 999-1010